Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer.

ABSTRACT:

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC10318489 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature